MA49152A - ANTI-CD33 IMMUNOCONJUGATE DOSAGE SCHEDULES - Google Patents
ANTI-CD33 IMMUNOCONJUGATE DOSAGE SCHEDULESInfo
- Publication number
- MA49152A MA49152A MA049152A MA49152A MA49152A MA 49152 A MA49152 A MA 49152A MA 049152 A MA049152 A MA 049152A MA 49152 A MA49152 A MA 49152A MA 49152 A MA49152 A MA 49152A
- Authority
- MA
- Morocco
- Prior art keywords
- dosage schedules
- immunoconjugate
- immunoconjugate dosage
- schedules
- dosage
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762507636P | 2017-05-17 | 2017-05-17 | |
US201762523112P | 2017-06-21 | 2017-06-21 | |
US201762579779P | 2017-10-31 | 2017-10-31 | |
US201762596377P | 2017-12-08 | 2017-12-08 | |
US201862660096P | 2018-04-19 | 2018-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49152A true MA49152A (en) | 2020-03-25 |
Family
ID=64274787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049152A MA49152A (en) | 2017-05-17 | 2018-05-16 | ANTI-CD33 IMMUNOCONJUGATE DOSAGE SCHEDULES |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3624839A4 (en) |
JP (1) | JP2020519640A (en) |
MA (1) | MA49152A (en) |
WO (1) | WO2018213430A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200276339A1 (en) * | 2017-12-04 | 2020-09-03 | Actinium Pharmaceuticals, Inc. | Methods for treatment of patients with myelodysplastic syndromes |
EP3737421A4 (en) | 2018-01-12 | 2022-03-16 | Immunogen, Inc. | Methods for antibody drug conjugation, purification, and formulation |
TW202003048A (en) | 2018-05-15 | 2020-01-16 | 美商伊繆諾金公司 | Combination treatment with antibody-drug conjugates and FLT3 inhibitors |
CA3101943A1 (en) * | 2018-06-07 | 2019-12-12 | Magenta Therapeutics, Inc. | Therapeutic methods using antibody drug conjugates (adcs) |
WO2020264211A1 (en) * | 2019-06-26 | 2020-12-30 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibodies for treating cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ539395A (en) * | 2002-11-07 | 2009-01-31 | Immunogen Inc | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
EP3145542A4 (en) * | 2014-05-20 | 2018-01-17 | ImmunoGen, Inc. | Methods for characterizing and treating acute myeloid leukemia |
-
2018
- 2018-05-16 MA MA049152A patent/MA49152A/en unknown
- 2018-05-16 WO PCT/US2018/032945 patent/WO2018213430A1/en unknown
- 2018-05-16 EP EP18802489.7A patent/EP3624839A4/en not_active Withdrawn
- 2018-05-16 JP JP2019562396A patent/JP2020519640A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3624839A1 (en) | 2020-03-25 |
JP2020519640A (en) | 2020-07-02 |
WO2018213430A1 (en) | 2018-11-22 |
EP3624839A4 (en) | 2021-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47575A (en) | MONOCYCLIC OGA INHIBITOR COMPOUNDS | |
MA49152A (en) | ANTI-CD33 IMMUNOCONJUGATE DOSAGE SCHEDULES | |
MA49006A (en) | IP6K INHIBITORS | |
FR3022462B1 (en) | ORAL COMPOSITION OF ANTI-TNFALPHA ANTIBODY | |
MA43873A (en) | INJECTION DSPOSITIVE | |
DK3672948T3 (en) | PYRIDINAMINE-PYRIDONE AND PYRIMIDINAMINE-PYRIDONE COMPOUNDS | |
MA50156A (en) | ANTIBODY VARIANTS | |
MA43764A (en) | MONOVALENT INHIBITOR OF THE HUTNFR1 INTERACTION | |
DK3672967T3 (en) | AZAINDOLYLPYRIDON AND DIAZAINDOLYLPYRIDON COMPOUNDS | |
IT201700035964A1 (en) | "DIVIDING FOR BOISERIE" | |
ITUA20163609A1 (en) | "MICRO-COGENERATOR". | |
IT201700090331A1 (en) | "LOPEMIDE" | |
IT201700071679A1 (en) | REMEMBEBE ' | |
UA37095S (en) | BANDAGE BANDAGE | |
UA38250S (en) | JEWELRY "EARRINGS-HANGERS" | |
UA36981S (en) | JEWELRY BOX "OCTOGAN" | |
UA37083S (en) | JEWELRY BOX "ROUND" | |
MA49488A (en) | ANTIBODY VARIANTS | |
MA47058A (en) | ANTIBODY VARIANTS | |
UA38254S (en) | NECKLACE "COPECHOKER" | |
GB201710281D0 (en) | Single mask transistor 2017 | |
UA36688S (en) | BOTTLE "LTAVA" | |
UA38200S (en) | DEVICE FOR INJECTIONS | |
UA36043S (en) | PACKAGING-LABEL FOR "FRUKFETTA" SWEETS | |
UA35844S (en) | LOGO "PHARMACY OF LOW Ts" |